Twist Bioscience (NASDAQ:TWST) Director Sells $470,000.00 in Stock

Twist Bioscience Corporation (NASDAQ:TWST) Director Robert Chess sold 10,000 shares of the business’s stock in a transaction dated Tuesday, March 17th. The shares were sold at an average price of $47.00, for a total value of $470,000.00. Following the sale, the director owned 21,084 shares of the company’s stock, valued at approximately $990,948. This represents a 32.17% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.

Twist Bioscience Price Performance

NASDAQ TWST opened at $42.07 on Friday. The company has a 50-day moving average price of $45.85 and a 200-day moving average price of $35.85. Twist Bioscience Corporation has a 52 week low of $23.30 and a 52 week high of $57.88. The company has a quick ratio of 3.37, a current ratio of 3.78 and a debt-to-equity ratio of 0.03. The firm has a market capitalization of $2.58 billion, a P/E ratio of -32.87 and a beta of 2.23.

Twist Bioscience (NASDAQ:TWST) last posted its quarterly earnings data on Monday, February 2nd. The company reported ($0.50) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.48) by ($0.02). Twist Bioscience had a negative return on equity of 27.16% and a negative net margin of 19.56%.The business had revenue of $103.70 million during the quarter, compared to analysts’ expectations of $100.32 million. Twist Bioscience’s revenue for the quarter was up 16.9% compared to the same quarter last year. Equities research analysts anticipate that Twist Bioscience Corporation will post -2.12 earnings per share for the current year.

Wall Street Analyst Weigh In

TWST has been the subject of several analyst reports. Weiss Ratings restated a “sell (d-)” rating on shares of Twist Bioscience in a research note on Monday, December 29th. TD Cowen reiterated a “buy” rating on shares of Twist Bioscience in a research report on Thursday, January 8th. Barclays boosted their price target on Twist Bioscience from $39.00 to $50.00 and gave the company an “overweight” rating in a report on Tuesday, February 3rd. Robert W. Baird set a $50.00 price target on Twist Bioscience in a research report on Tuesday, February 3rd. Finally, Evercore raised their price objective on Twist Bioscience from $42.00 to $52.00 and gave the stock an “outperform” rating in a research note on Tuesday, February 3rd. Seven equities research analysts have rated the stock with a Buy rating and two have issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $45.88.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of the company. Royal Bank of Canada boosted its holdings in Twist Bioscience by 11.8% in the 1st quarter. Royal Bank of Canada now owns 40,373 shares of the company’s stock worth $1,585,000 after buying an additional 4,254 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its holdings in Twist Bioscience by 4.7% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 70,310 shares of the company’s stock valued at $2,765,000 after acquiring an additional 3,181 shares during the period. Goldman Sachs Group Inc. lifted its position in shares of Twist Bioscience by 4.2% in the first quarter. Goldman Sachs Group Inc. now owns 932,978 shares of the company’s stock valued at $36,629,000 after acquiring an additional 37,577 shares in the last quarter. Intech Investment Management LLC lifted its position in shares of Twist Bioscience by 18.9% in the first quarter. Intech Investment Management LLC now owns 28,917 shares of the company’s stock valued at $1,135,000 after acquiring an additional 4,591 shares in the last quarter. Finally, Geode Capital Management LLC boosted its stake in shares of Twist Bioscience by 0.3% in the second quarter. Geode Capital Management LLC now owns 1,424,377 shares of the company’s stock worth $52,410,000 after acquiring an additional 4,438 shares during the period.

About Twist Bioscience

Twist Bioscience Corporation is a synthetic biology company specializing in the development and commercialization of DNA-based products and solutions. Founded in 2013 and headquartered in South San Francisco, California, the company has pioneered a proprietary silicon-based DNA synthesis platform designed for high-throughput production of synthetic genes and oligonucleotides. Twist leverages semiconductor manufacturing techniques to enable precise, scalable synthesis of DNA at speeds and volumes unattainable with traditional methods.

At the core of Twist’s offering is its proprietary platform that automates the synthesis of custom DNA fragments, gene libraries, and long oligonucleotides.